Leaders at FDA share highlights and updates for drugs and biologics at RAPS Convergence

Top officials from FDA’s Centers for drugs and biologics—including Center for Biologics Evaluation and Research (CBER) Director Peter Marks—provided high-level updates at RAPS Convergence 2023 this week. The briefing covered recent operational changes, recent accomplishments, and near-future projects.

Fill out the form to read the full article.